Article Details
Retrieved on: 2024-07-12 19:27:44
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here